{
  "docId": "019de076-3901-734c-833f-b5b0e2d3aa41",
  "docSlug": "e86c5f257c7f518e1f9c16c922f96c7d",
  "documentTitle": "Exscientia | Investor Presentation Deck | 76 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 76,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3901-734c-833f-b5b0e2d3aa41/31",
  "deckHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41",
  "deckJsonHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41.json",
  "deckAnchorHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.67,
        "x": 0.24,
        "y": 0.335
      },
      "kind": "diagram",
      "text": "Part 1: Dose Escalation to Part 2: Dose Expansion",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39871b6a-4d0a-4bed-a44f-31094b7bbda1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "ELUCIDATE (protocol number GTAEXS617-001) is a Phase 1/2 open-label multi-centre study... *Solid tumours under consideration include ovarian cancer, pancreatic cancer, HR+ HER2- breast cancer, head & neck cancer, NSCLC and colorectal cancer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67f5dea7-538b-4e95-a23b-c4b02f7293ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.25,
        "y": 0.41
      },
      "kind": "list",
      "text": "Part A: Monotherapy; Part B: Combination with SoC; n=up to 30 patients; Data-informed prioritisation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19aa5d6c-485c-429c-bbb2-e996fc13cb8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.62,
        "y": 0.41
      },
      "kind": "list",
      "text": "n=30-60 patients with monotherapy; n=30-60 patients with combination; n will depend on number of disease specific cohorts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9350fd1d-51cb-434b-bf86-8a48fc207783",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "Additional data generation, including clinical endpoints, peripheral and tumour multi-omics, and correlation of data and response to previously collected ex vivo results planned",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db3befa3-c1d2-4942-843e-f7cd19402300",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Preclinically identified PD biomarkers to be further assessed in the trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b442b371-04c4-4d56-b12c-47c48611eb51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d929cd83-7055-4c6f-91bb-aa4c55f0c252",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "c7928283-3c06-4995-bf79-85891ae7e0d3",
      "evidence": "title/action-title: Preclinically identified PD biomarkers to be further assessed in the trial",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "02fa0eea-4b96-46de-837a-4feecc87cd54",
      "evidence": "The slide uses a horizontal flow to represent the progression of a clinical trial from Part 1 to Part 2.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}